09 - Scientific and electric apparatus and instruments
Goods & Services
Scientific apparatus, instruments and devices, not for
medical use, namely, applicators for plates for collection
and detection of contaminants in industrial, agri-food,
cosmetic and pharmaceutical products and in the production
environment for these products, namely, water, air, and
surfaces environments, and for in-vitro diagnosis.
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Logiciel et programme d’ordinateur dédié à la gestion du laboratoire de microbiologie. logiciel-service (SaaS) dédié à la gestion du laboratoire de microbiologie.
3.
METHOD AND SYSTEM FOR IDENTIFYING MICRO-ORGANISMS TAKING COLONY FORM
The invention relates to a method for identifying a microbial strain taking the form of a colony, comprising acquiring a set of at least three spectral channels of the colony contained in the visible and infrared spectrum; and making, by means of a computer, a prediction of the species depending on the acquired spectral channels. The three channels of said set that contribute the most to the performance of the prediction are selected from a first spectral band [730-780] nm and from a second spectral band [550-650] nm.
G01N 21/31 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
C12Q 1/04 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
G01N 21/359 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light
G01J 3/12 - Generating the spectrum; Monochromators
4.
OPTICAL DEVICE FOR TAKING FLUORESCENCE AND ABSORBANCE MEASUREMENTS
The present document relates to an optical device configured to measure fluorescence and absorbance in an immunoassay and in wet chemistry, comprising: - an illuminator channel (26) comprising at least one excitation source (28), - a detector channel (34) comprising at least one sensor (36), - a cuvette (130) containing a sample (132) between the illuminator channel (26) and the detector channel (34), - a mixer (38) of optical light between the illuminator channel (26) and the cuvette (130) and a beam splitter (40) between the cuvette (130) and the detector channel (34).
G01N 21/31 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
G01N 21/25 - Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
C12Q 1/04 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
Escherichia ColiEscherichia Coli (STEC) which may be present in a sample comprising enterobacteria, comprising the following steps: - performing lysis of the sample, enabling lysis of the STECs in order to obtain a solution comprising the nucleic acids thereof; - bringing the solution of nucleic acids into contact with primers, making it possible to amplify at least the stx1 and/or stx2 gene or gene fragment; - if at least one of the stx1 and/or stx2 genes or gene fragments is amplified, part of the sample is deposited on an agar reaction medium comprising ■ at least one toxin inducer, ■ at least one agglutinating conjugate formed by at least one binding partner specific to the STX1 protein and/or at least one binding partner specific to the STX2 protein, which binding partner(s) is (are) coupled to a nanoparticle; - detecting and confirming the presence of at least one STEC by the appearance of a halo on the agar around the STEC.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
C12Q 1/04 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
The invention relates to a method for detecting colonies of microorganisms in a biological sample arranged in a solid culture medium, the method being implemented by a detection system comprising at least one incubator, an analysis unit, and at least one automated image capture system, the method comprising a first phase of detecting and counting objects, in the field of view of the image capture system, exhibiting growth, and a second phase applied only to those samples deemed to be negative in the first phase of the method, the second phase being based on anomaly detection applied to at least the last image acquired in the incubation sequence.
C12M 1/00 - Apparatus for enzymology or microbiology
C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
C12Q 1/04 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
C12M 1/36 - Apparatus for enzymology or microbiology including condition or time responsive control, e.g. automatically controlled fermentors
C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
10.
MANUFACTURE OF POLYMERASE CHAIN AMPLIFICATION KITS OPTIMIZING AN AMPLIFICATION HYBRIDIZATION PHASE
Disclosed is a method for digitally simulating a polymerase chain amplification of at least one target, comprising the simulation of a plurality of successive cycles of the amplification, each cycle comprising: a hybridization phase; an elongation phase; then a denaturation phase; wherein the hybridization phase comprises, for each cycle: obtaining, for the cycle, an initial value of a vector of concentrations of a plurality of nucleic acid molecules in the form of single strands; initializing a matrix of concentrations of duplexes formed by the hybridization of the plurality of nucleic acid molecules in the form of single strands; calculating the change in the matrix of concentrations during the hybridization phase by applying, to the matrix of concentrations, a matrix differential equation representing the kinetics of the duplex formation according to the concentrations of the plurality of nucleic acid molecules.
Disclosed is a method for digitally simulating a polymerase chain amplification of at least one target, comprising the simulation of a plurality of successive cycles of the amplification, each cycle comprising, sequentially: a hybridization phase; an elongation phase; then a denaturation phase; wherein, for each cycle: the hybridization phase comprises: obtaining, for the cycle, an initial value of a vector of concentrations of a plurality of nucleic acid molecules in the form of single strands; calculating a matrix of concentrations of partial duplexes formed by the hybridization of the plurality of nucleic acid molecules in the form of single strands; the denaturation phase comprises: multiplying a vector of the concentration of elongated duplexes resulting from the application of the elongation phase to the concentrations of duplexes, by an elongated duplex denaturation tensor.
A method for determining in vitro or ex vivo the immune status of an individual, preferably a patient, including a step of detecting and/or quantifying the expression of one or more HERV/MaLR sequences in a biological sample of the individual. Also relates to the tools for implementing the method and to the uses thereof.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
13.
METHOD FOR DETERMINING THE SUSCEPTIBILITY OF A MICROORGANISM TO AN ANTIMICROBIAL AGENT
The present invention relates to a method for predicting the susceptibility of a microbial strain to an antimicrobial agent, the method being characterized in that it comprises implementation, by data-processing means (4) of a client (2), of steps of: (a) obtaining a hyperspectral image between 390 nm and 900 nm representing at least one colony of said strain in a sample devoid of antimicrobial agent (22); (b) determining a spectrum of the colony based on pixels of said hyperspectral image corresponding to said colony, “test spectrum” below; (c) comparing said test spectrum with microbial classes of a database of predetermined data, “reference microbial class” below, said classes corresponding to a taxonomic level lower than species and being learnt using at least one hyperspectral spectrum of a microbial strain, the database containing, for each reference microbial class, the susceptibility to the microbial agent of the reference microbial class; (d) determining the susceptibility of the microbial strain to the microbial agent to be the susceptibility associated with the reference microbial class closest to the test hyperspectral spectrum.
The invention relates to a ready-to-use calibration composition for a mass spectrometer, comprising whole E. coli bacteria suspended in a liquid which is based on alcohol (s) and/or acetonitrile and is sanitizing, volatile and does not denature bacterial proteins.
The invention relates to a microbiological typing method, which comprises providing: a database of genetic profiles of microbial strains; and a phylogenetic tree of assignments of the genetic profiles to positions in the phylogenetic tree, and of frequencies of variation of the profiles in the tree. The typing of a microorganism comprises: measuring the genetic profile of the microorganism; determining a probability of variation of each genetic profile in the database with respect to the measured genetic profile, the probability of variation being calculated as a function of the frequencies of variation; and determining that the microorganism belongs to a taxon of the tree if at least the probability of variation for the taxon is greater than a threshold. According to the invention, the phylogenetic tree is constructed from a core genome of the microorganism species, and the predefined set of genetic markers is chosen from an accessory genome of the microorganism species.
The invention relates to a microbiological typing method, which comprises providing a database of genetic profiles of microbial strains, a phylogenetic tree, assignments of the genetic profiles to positions in the phylogenetic tree, and frequencies of variation of the profiles in the tree. The typing of a microorganism comprises measuring the genetic profile of the microorganism, determining probabilities of variation of the genetic profiles belonging to the groups with respect to the measured genetic profile, the probabilities of variation being calculated as a function of the frequencies of variation at a predefined level of the phylogenetic tree and of the belonging of the microorganism to one of the microbial groups if an identification performance criterion is reached for the group, the criterion being reached if at least one probability of variation for the group is greater than a first predefined threshold.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Chemical preparations for industry and research; chemical
preparations for scientific use; chemical reagents and
biological preparations for diagnosis, other than for
medical use; reagents and culture media for the control,
detection, diagnosis and analysis of contaminating
microorganisms and substances in industrial, agri-food,
cosmetic and pharmaceutical products; reagents and media
enabling the control, diagnosis and analysis of
contaminating microorganisms and substances for detecting
biological threats and monitoring epidemics and pandemics. Reagents and culture media for medical and veterinary
diagnosis; laboratory reagents for use in clinical, medical
or veterinary laboratories; chemical, biochemical and
biological preparations for use in the medical and
veterinary fields; reagents and culture media for medical
and veterinary use enabling the control, diagnosis and
analysis of contaminating microorganisms and substances for
detecting biological threats and monitoring epidemics and
pandemics. Diagnostic apparatus and instruments, not for medical use;
scientific analysis and diagnostic apparatus and
instruments, other than for medical use; laboratory
instruments; Scientific apparatus and instruments for the
monitoring, detection, diagnosis and analysis of
contaminating substances in industrial, agri-food, cosmetic,
pharmaceutical and veterinary products; scientific apparatus
and instruments enabling the control, diagnosis and analysis
of contaminating microorganisms and substances for detecting
biological threats and monitoring epidemics and pandemics;
software for analyzing, processing and interpreting medical
and veterinary test results in the field of in vitro
diagnosis. Apparatus and instruments for medical and veterinary
diagnostic purposes; apparatus and instruments for medical
and veterinary use enabling the control, diagnosis and
analysis of contaminating microorganisms and substances for
detecting biological threats and monitoring epidemics and
pandemics.
18.
Methods For Determining Antimicrobial Drug Resistance
The present invention provides for the prediction or detection of antimicrobial drug resistance in a microorganism, particularly in a pathogenic microorganism, by determining the presence or absence of antimicrobial resistance markers (AMRs) in the microorganism. This allows for the rapid determination of whether a microorganism is resistant to one or more antimicrobial drugs. The microorganism can be obtained from a patient suffering or suspected of suffering from an infection by the microorganism, and once the determination is made, the patient can be given an antimicrobial drug to which the microorganism is not resistant.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
A method for quantifying endotoxins in a biological sample with an analysis medium added to the field of view of an imager, the analysis medium including at least one analysis chamber and a plurality of reference chambers, including the steps of, for each of a plurality of measuring times of a measuring period: a) acquiring an image and determining light intensity valves in the reference and analysis chambers; b) determining a calibration relationship connecting the light intensity value and the concentration at this measuring time; c) determination of at least one endotoxin concentration in a biological sample from said calibration relationship and the intensity value in the analysis chamber at said measurement time; the method subsequently including the step of d) determining a temporal evolution of an endotoxin concentration in the biological sample over the course of the measuring period from the endotoxin concentration for a plurality of measurement times.
G01N 21/77 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
20.
METHOD AND KIT FOR DETECTING A REPLICATING RESPIRATORY VIRUS
A method for determining, in vitro or ex vivo, the presence in a patient of an infection by a replicating respiratory virus, including a step i) of determining, in a test sample taken from the mouth or nose of said patient, the level of transcripts of at least one marker gene selected from the interferon-stimulated genes, referred to as ISGs; and associated kits.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
A61B 10/00 - Other methods or instruments for diagnosis, e.g. for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
The invention relates to a filtration device for use in solid-phase cytometry, said filtration device being configured to filter a biological sample likely to contain microorganisms and to allow its analysis, the filtration device comprising: a filtration membrane configured to filter the biological sample, the filtration membrane having an upper face and a lower face, characterized in that the filtration device further comprises at least: a coverslip arranged above the upper face of the filtration membrane, the coverslip being arranged so as to cover the entirety of the upper face of the membrane, an interstitial space formed between the coverslip and the upper face of the filtration membrane, the interstitial space being shaped to receive a fluid.
The invention relates to a method for determining the susceptibility of a strain of Mycobacterium tuberculosis to pyrazinamide, the method comprising the following steps: (i) determining the presence in the genome of this strain of at least one mutation in the rpoB gene between positions 761112 and 761182; and (ii) determining the sensitive or resistant nature of this strain depending on the presence or absence of the at least one mutation. The invention also relates to a kit comprising means for detecting at least one sequence chosen from among the sequences SEQ ID NO: 1 to 3 and to the use of this same kit for determining the susceptibility of a strain of Mycobacterium tuberculosis to pyrazinamide.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Chemical preparations for industry and research; chemical preparations for scientific use; chemical reagents and biological preparations for diagnosis, other than for medical use; reagents and culture media for the control, detection, diagnosis and analysis of contaminating microorganisms and substances in industrial, agri-food, cosmetic and pharmaceutical products; reagents and media enabling the control, diagnosis and analysis of contaminating microorganisms and substances for detecting biological threats and monitoring epidemics and pandemics. Reagents and culture media for medical and veterinary diagnosis; laboratory reagents for use in clinical, medical or veterinary laboratories; chemical, biochemical and biological preparations for use in the medical and veterinary fields; reagents and culture media for medical and veterinary use enabling the control, diagnosis and analysis of contaminating microorganisms and substances for detecting biological threats and monitoring epidemics and pandemics. Diagnostic apparatus and instruments, not for medical use; scientific analysis and diagnostic apparatus and instruments, other than for medical use; laboratory instruments; Scientific apparatus and instruments for the monitoring, detection, diagnosis and analysis of contaminating substances in industrial, agri-food, cosmetic, pharmaceutical and veterinary products; scientific apparatus and instruments enabling the control, diagnosis and analysis of contaminating microorganisms and substances for detecting biological threats and monitoring epidemics and pandemics; software for analyzing, processing and interpreting medical and veterinary test results in the field of in vitro diagnosis. Apparatus and instruments for medical and veterinary diagnostic purposes; apparatus and instruments for medical and veterinary use enabling the control, diagnosis and analysis of contaminating microorganisms and substances for detecting biological threats and monitoring epidemics and pandemics.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Chemicals used in industry, Chemical preparations for research; Chemical preparations for scientific purposes; Chemical diagnostic reagents, Biological diagnostic preparations, not for medical purposes; Reagents and Growing media, for use in the following fields: Monitoring, detection, diagnosis and analysis of microorganisms and contaminants in industrial goods, agri-foodstuffs, cosmetics and pharmaceuticals; Reagents and media for monitoring, diagnosing and analysing microorganisms and contaminants, for use in the following fields: Detection of biological threats and surveillance of epidemics and pandemics. Reagents and culture media, for use in the following fields: medical diagnosis and Veterinary diagnosis; Laboratory reagents for clinical, medical or veterinary laboratories; Chemical, biochemical and biological preparations, for use in the following fields: Medicine and Veterinary medicine; Reagents and media enabling the monitoring, diagnosis and analysis of microorganisms and contaminants, For medical purposes and Veterinary use, for use in the following fields: Detection of biological threats and surveillance of epidemics and pandemics. Diagnostic apparatus and instruments, not for medical purposes; Scientific analysis and diagnostic apparatus and instruments, Not for medical purposes; Laboratory instruments; Scientific apparatus and instruments, for use in the following fields: Monitoring, detection, diagnosis and analysis of contaminants in industrial goods, agri-foodstuffs, cosmetics, pharmaceuticals and veterinary goods; Scientific apparatus and instruments for monitoring, diagnosing and analysing microorganisms and contaminants, for use in the following fields: Detection of biological threats and surveillance of epidemics and pandemics; Software for analysis, processing and interpretation of medical and veterinary test results in the field of in vitro diagnosis. Instruments and apparatus for medical and veterinary diagnosis; Apparatus and instruments for monitoring, diagnosing and analysing microorganisms and contaminants, For medical and veterinary purposes, for use in the following fields: Detection of biological threats and surveillance of epidemics and pandemics.
25.
GENETIC RESISTANCE PREDICTION AGAINST ANTIMICROBIAL DRUGS IN MIRCOORGANISMS USING STRUCTUREAL CHANGES IN THE GENOME
The invention relates to a method of determining an infection of a patient with at least one microorganism, particularly a bacterial microorganism, potentially resistant to antimicrobial drug treatment, a method of selecting a treatment of a patient suffering from an infection with at least one microorganism, particularly bacterial microorganism, and a method of determining structural changes of the genome of the microorganism, particularly bacterial microorganism, comprising at least one gene, as well as Computer program products used in these methods.
G16B 15/00 - ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
C12Q 1/04 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
G16B 40/00 - ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
26.
USING THE FULL REPERTOIRE OF GENETIC INFORMATION FROM BACTERIAL GENOMES AND PLASMIDS FOR IMPROVED GENETIC RESISTANCE TESTS
The invention relates to a method of determining an antimicrobial drug resistance profile for a microorganism, wherein nucleic acid sequences of the microorganism are analyzed for at least two genetic variations of the nucleic acid sequences comprising at least one genetic variation in a chromosome and at least one genetic variation in at least one plasmid, as well as a, e.g. diagnostic, method of determining an infection of a patient with a microorganism potentially resistant to antimicrobial drug treatment and a method of selecting a treatment of a patient suffering from an infection with a potentially resistant microorganism, wherein the data of the antimicrobial drug resistance profile are applied.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
27.
METHOD USING A TRANSCRIPTOMIC SCORE FOR ASSESSING THE CLINICAL OUTCOME OF A PATIENT IN A CLINICAL SETTING, AND MEANS FOR ITS IMPLEMENTATION
The invention relates to a method of determining, from an assayed sample or a population of assayed samples previously drawn from patients, a transcriptomic score (TScore) suitable for assessing a risk of adverse clinical outcome for patients in a clinical setting, said method involving, amongst other steps, the measurement of gene expression values on a patient sample or a population of samples previously obtained from patients for at least two distinct genes selected among a predetermined set of genes, and the determination of a transcriptomic score where the genes are assigned or not assigned a point. The method can be computer-implemented. The genes of the predetermined set of genes can be at least two genes selected among: ADGRE3, ARL14EP, BPGM, C3AR1, CCNB1IP1, CD177, CD274, CD3D, CD74, CIITA, CTLA4, CX3CR1, GNLY, IFNgamma, IL10, IL1R2, IL1RN, IL7R, IP10/CXCL10, MDC1, OAS2, S100A9, TAP2, TDRD9, TNF and ZAP70. The method can be implemented on assayed biological sample(s) drawn from patient(s) which have been admitted in a reanimation unit, an intensive or continuing care unit. The invention also relates to a method to classify a sample previously drawn from a patient, in a group reflecting a risk of adverse clinical outcome in a clinical setting, or to identify a patient at risk of adverse clinical outcome in a clinical setting, as well as an in vitro or ex vivo method of screening whether a drug has the capacity to alleviate an adverse clinical outcome in a patient. The invention also relates to computer means for implementing the invention, and the use of a kit for carrying out a method of the invention.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
28.
SYSTEMS AND METHODS FOR TARGETING TESTING PANEL BASED ON TEMPORAL, GEOGRAPHIC, AND DEMOGRAPHIC DATA
Methods for targeting the results provided by a testing panel based on patient population data are provided, comprising: identifying, by one or more processors, a set of relevant pathogen groups for each of a respective one or more populations of interest; obtaining, by the one or more processors, pathogen testing results for a particular individual, corresponding to a plurality of pathogen groups; and reporting, by the one or more processors, to a device associated with an individual or a medical provider of the individual, the pathogen testing results for the particular individual, corresponding to the set of relevant pathogen groups for a population, of the one or more populations of interest, with which the individual is associated.
G01N 33/487 - Physical analysis of biological material of liquid biological material
G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
G16H 50/80 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
G16H 10/00 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data
29.
MODIFIED IMMUNO-MOLECULAR ASSAY FOR FASTER BIOMARKER DETECTION
The present invention relates to an improved immuno-molecular assay, for example a Proximity Extension Assay protocol or a Proximity Ligation Assay (PLA) protocol, which is more compatible with the assay durations that are expected in the context of point-of-care diagnostics. In particular, the time needed for performing the Proximity Extension Assay protocol of the invention is reduced by more than 13-folds as compared to classical Proximity Extension Assay protocols, without significantly affecting the performance of the assay for protein detection. Thus, the method of the invention provides a more rapid and simpler procedure to screen and diagnose diseases in a non-invasive way. The use of such a method in an integrated system is an exciting and expected improvement in clinical diagnostics for the detection of biomarkers in human samples.
G01N 33/542 - Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
C12Q 1/6804 - Nucleic acid analysis using immunogens
30.
METHOD FOR DETERMINING THE RISK OF INCIDENCE OF A CARE-RELATED INFECTION IN A PATIENT
An in vitro or ex vivo method for determining the risk of incidence of a healthcare-associated infection in a patient, including a step of measuring the expression of at least one gene encoding a pro-inflammatory cytokine receptor located on chromosome 2 in the region 2q11-2q12, in a biological sample from the patient.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
09 - Scientific and electric apparatus and instruments
Goods & Services
Scientific apparatus, instruments and devices, not for medical use, namely, applicators for plates for collection and detection of contaminants in industrial, agri-food, cosmetic and pharmaceutical products and in the production environment for these products, namely, water, air, and surfaces environments, and for in-vitro diagnosis
32.
METHOD FOR DETECTING THE PRESENCE OF POLYMERS IN A SPECTRUM OBTAINED BY MASS SPECTROMETRY
The invention relates to a method for detecting the presence of a signal from a polymer in spectra obtained by mass spectrometry of biological samples, the method comprising a step (101) of determining a set of at least one parameter, referred to as a descriptor, of the presence of the polymer, a step (103) of assigning a score to each value of each descriptor, and a step (105) of classifying the scores into a class of positive spectra containing no polymer and a class of negative spectra containing the polymer.
G16B 40/10 - Signal processing, e.g. from mass spectrometry [MS] or from PCR
G16C 20/00 - Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
C12Q 1/04 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
Methods and devices are provided for simultaneously amplifying a plurality of sample wells for a predetermined amount of amplification, detecting whether amplification has occurred in a first set of the wells, amplifying for an additional amount of amplification and detecting whether amplification has occurred in a second set of the wells. Methods are also provided for analyzing a target nucleic acid sequence using melt curves that were generated in a plurality of amplification cycles.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
It is disclosed a method for performing fluorescence measurement on a sample, comprising: Illuminating the sample using a light source, acquiring at least one fluorescence image of the illuminated sample, and processing the fluorescence image to determine a fluorescence intensity of the sample, characterized in that processing the fluorescence image to determine a fluorescence intensity of the sample comprises: extracting, from the fluorescence image, a region of interest (ROI) free from artefacts, by application of a trained model, and determining the fluorescence intensity of the sample from the extracted region of interest.
The disclosure relates to a sample collection device (1, 100) comprising a support (10, 110) arranged to collect and release microbiological fluids, the sample collection device further comprising a head (7, 107), said head (7, 107) being configured to cooperate with a spout (6) of an analysis device (2) in such a way that the cooperation between the head (7, 107) and the spout (6) causes microbiological fluid to be released inside the analysis device (2).
A61B 10/00 - Other methods or instruments for diagnosis, e.g. for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Chemical preparations for industry and research; chemical
reagents and biological preparations for diagnosis, other
than for medical use; chemical preparations for scientific
use; reagents and culture media for controlling, detecting,
diagnosing and analyzing contaminating substances in
industrial, agri-food, cosmetic, pharmaceutical and
environmental products. Reagents and culture media for medical, pharmaceutical and
veterinary diagnosis; laboratory reagents for clinical or
medical laboratories; biological preparations for medical or
veterinary use.
C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
41.
CULTURE MEDIUM FOR DETECTING MICROORGANISMS COMPRISING A MIXTURE OF AGAR AND KAPPA-CARRAGEENAN AS GELLING AGENT
The invention relates to the field of molecular biology and more particularly that of clinical and industrial microbiology. More specifically, the present invention relates to a culture medium for detecting microorganisms, comprising, as a gelling agent, a mixture of agar and kappa-carrageenan.
C12Q 1/04 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
The present invention relates to a method of determining an infection of a patient with at least one microorganism, particularly a bacterial microorganism, potentially resistant to antimicrobial drug treatment, a method of selecting a treatment of a patient suffering from an infection with at least one microorganism, particularly bacterial microorganism, and a method of determining an antimicrobial drug, e.g. antibiotic, resistance profile for at least one microorganism, particularly bacterial microorganism, as well as computer program products used in these methods.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
A method for quantifying at least one microorganism group via at least one mass spectrometry analysis. The method includes at least one separation and fragmentation step. The method moreover includes a step that involves measuring the amount of at least one representative peptide or at least one protein representing the microorganism group. The at least one representative peptide or the at least one protein is obtained after the at least one separation and fragmentation step and serves as a quantification marker(s). The amount of the quantification marker(s) is directly correlatable to the amount of the at least one microorganism group.
A system for diluting a sample of biological material, including a fluid circuit, wherein the fluid circuit includes at least: a first container configured to contain a sample of biological material containing a biological material to be diluted, the sample being a fluid; a second container configured to contain a first dilution fluid; and at least one first metering member for metering a predetermined volume of fluid, including a first wall and a second wall, the first metering member including a metering zone configured to change at least from an initial state in which the first wall and the second wall are in contact with one another to an operating state in which the first wall and the second wall are separated from one another.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
An analysis plate configured to allow a characterization of microorganisms by mass spectrometry, wherein the analysis plate includes at least one analysis zone configured for a biological sample containing a population of at least one microorganism, wherein all or part of the analysis zone is made of a porous material, the analysis zone including at least one antimicrobial agent.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
H01J 49/04 - Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locks; Arrangements for external adjustment of electron- or ion-optical components
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
G16B 25/10 - Gene or protein expression profiling; Expression-ratio estimation or normalisation
Detection method for sample presence and device associated The invention relates to a detection method of liquid presence inside a well of a transparent or translucent support intended for analysis performed in a device for in vitro detection and/or quantification, the presence of liquid being assessed on the basis of an index of visible pattern likelihood representative of the probability of a pattern to be legible as expected in the field of view of an imager. Said invention allows preventing assay execution without sample and can be applied without wasting sample or sample well support in case of the sample well is not filled by the user. Moreover, this method allows a precise detection of the samples that are transparent or translucent, with low reflectance.
The present invention relates to a method for in vitro or ex vivo detection of an immunocompromised status in a subject, comprising quantifying, in a biological sample of said subject, the expression of at least 2 target genes selected from the group consisting of TAP2, C3AR1, CD177 and IL1R2, and identifying whether or not a variation in their expression is present as compared to a reference value. The invention also relates to tools for implementing said method, and to uses thereof.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
The present disclosure relates to methods and systems suitable for simultaneously amplifying a number of potential targets and then performing a melt detection based on whether or not any amplification is detected for any target nucleic acid(s), wherein the melt parameters are limited by the melt temperature range characteristic for the target nucleic acid(s) for which amplification is detected. This invention retains the resolution achieved by nucleic acid melts with a slow, steady ramp rate between the annealing and denaturation temperatures, but does so faster by using faster ramp rates at temperatures where no melt signature is expected from the reaction, and slower at temperatures where a melt signature is expected from the reaction.
A separation container for extracting a portion of a sample for use or testing and method for preparing samples for downstream use or testing are provided. The separation container may include a body defining an internal chamber. The body may define an opening, and the body may be configured to receive the sample within the internal chamber. The separation container may further include a seal disposed across the opening, such that the seal may be configured to seal the opening of the body, and a plunger movably disposed at least partially inside the internal chamber. The plunger may be configured to be actuated to open the seal and express the portion of the sample.
The present invention relates to in vitro or ex vivo methods and kits for determining the viral or bacterial nature of an infection on the basis of a biological sample of a patient by identifying the change in the level of expression of a plurality of biomarkers. In particular, the method comprises the steps of (a) measuring the expression of at least one viral target gene and of at least one bacterial target gene chosen from among OLAH, FAM20A, IL1R2, MMP8, RETN and SLC1A2; (b) comparing the expressions measured in step (a) with reference expression values for these target genes; and (c) on the basis of the results of the comparison, concluding whether the infection is viral or bacterial in nature .
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
54.
SYSTEMS, METHODS, AND APPARATUSES FOR CONCENTRATION AND IDENTIFICATION OF A MICROORGANISM FROM BLOOD
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
C12Q 1/24 - Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact microorganism
55.
METHODS AND COMPOSITIONS FOR TREATMENT OF RENAL INJURY AND RENAL FAILURE
A method of devising a therapy plan for renal replacement therapy (RRT) includes detecting a level of one or more biomarkers in a body fluid sample obtained from a subject. The level(s) may be correlated to an expected benefit from treatment with continued RRT and/or to an expected ability to successfully discontinue RRT. The method may include the step of assigning the subject to a predetermined subpopulation of individuals exhibiting a known status with regard to meeting criteria for continuing or discontinuing RRT. In some embodiments, the biomarker level is detected by introducing the body fluid into an assay instrument and contacting the body fluid to a binding reagent, for example, an antibody.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
G01N 33/48 - Biological material, e.g. blood, urine; Haemocytometers
G01N 33/487 - Physical analysis of biological material of liquid biological material
A method of analyzing a biological sample including biological agents and disposed in an analysis receptacle in a field of view of a holographic imaging system defining an acquisition focal plane, including, for each of a plurality of measurement times: acquiring a plurality of holographic images of the biological sample at different respective positions of the acquisition focal plane, and, from each acquired holographic image, determining a value of a biomass parameter representative of the quantity of biological agents at the position of the acquisition focal plane, the method including constructing a distribution indicator from values of the biomass parameter at the same measurement time for a plurality of positions of the acquisition focal plane, and providing, among the analysis results, a representation of the distribution of the biomass of biological agents, derived from at least one distribution indicator at a measurement time.
A method for classifying at least one input image representing a target particle in a sample, involves implementing, by data processing of a client, steps of: (b) extracting the characteristic map of the target particle by a convolutional neural network pre-trained on a base of public images; (c) classifying the input image according to the extracted characteristic map.
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
G06V 10/24 - Aligning, centring, orientation detection or correction of the image
G06V 10/44 - Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersections; Connectivity analysis, e.g. of connected components
G06V 10/774 - Generating sets of training patterns; Bootstrap methods, e.g. bagging or boosting
60.
METHOD AND SYSTEM FOR CHARACTERISING MICROORGANISMS BY DIGITAL HOLOGRAPHIC MICROSCOPY
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (France)
Inventor
Brault, Dylan
Fournier, Corinne
Olivier, Thomas
Faure, Nicolas
Abstract
The invention relates to a method for characterising microorganisms present in a biological sample, the method comprising acquiring a live holographic digital image of the sample, generating a focused image by using a digital model for reconstructing the focused image and characterising the bacteria on the basis of the focused image. According to the invention, prior to the holographic image being acquired, a plurality of calibration objects are provided in the acquisition field of view, which objects have a previously characterised dimension and refractive index and a shape chosen so that the interference patterns of the objects can be calculated using an image forming model for incorporating optical aberrations of the acquisition device. Prior to the focused image being computer generated, the optical aberrations are qualified according to the interference patterns of the objects and the calculated interference patterns and the digital model for reconstructing the focused image incorporates the quantified optical aberrations.
The subject matter is a method for determining the proliferation capacity of T lymphocytes in a subject, the method including the following steps: a) measuring the load of torque teno virus from a biological sample of the subject; and b) determining the proliferative capacity of the T lymphocytes based on the viral load measured in a).
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
62.
DETERMINING THE RISK OF DEATH OF A SUBJECT INFECTED WITH A RESPIRATORY VIRUS BY MEASURING THE EXPRESSION LEVEL OF THE OAS2 GENE
in vitroex vivoex vivo method for determining the risk of death for a subject infected with a respiratory virus, said method comprising the steps of measuring, in a biological sample from said subject, the expression level of the OAS2 gene, and comparing the expression level thus measured or a value derived from this amount to a predetermined reference value. The method thus makes it possible to conclude that there is an increased risk of death for the subject when a sub-expression of the OAS2 gene is statistically demonstrated from the biological sample. Advantageously, the measurement of the expression level of OAS2 can be supplemented by a measurement of one or more additional genes such as C3AR1, CD177, ADGRE3, CIITA, IL-10, IL1R2, CD74, TDRD9 and combinations thereof. Kits for measuring the expression of OAS2 and optionally one or more additional genes are also disclosed.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
63.
DETERMINING THE RISK OF DEATH OF A SUBJECT INFECTED WITH A RESPIRATORY VIRUS BY MEASURING THE EXPRESSION LEVEL OF THE CD74 GENE
The invention relates to an in vitro or ex vivo method for determining the risk of death in a subject infected with a respiratory virus, for example SARS-CoV-2, comprising a measurement, in a biological sample of said subject, of the level of expression of the CD74 gene; the invention also relates to associated kits.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
64.
DETERMINATION OF THE RISK OF DEATH OF A PATIENT INFECTED BY A RESPIRATORY VIRUS BY MEASURING THE EXPRESSION LEVEL OF THE ADGRE3 GENE
The invention relates to an in vitro or ex vivo determination method for determining the risk of death of a patient infected by a respiratory virus, said method comprising the steps of measuring, in a biological sample from said patient, the expression level of the ADGRE3 gene, and of comparing the expression level thus measured or a value derived from this quantity with a predetermined reference value. The method thus makes it possible to conclude that there is an increased risk of death of the patient when an underexpression of the ADGRE3 gene is statistically demonstrated from the biological sample. Advantageously, the measurement of the expression level of ADGRE3 can be supplemented by the measurement of one or more additional genes such as C3AR1, CD177, OAS2, CIITA, IL-10, IL1R2, CD74, TDRD9 and combinations thereof. The invention also relates to kits for measuring the expression of ADGRE3 and optionally of one or more additional genes.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
65.
FUNCTIONAL ASSAY FOR QUICKLY DETERMINING IMMUNE STATUS
The present invention relates to a method for quickly determining the immune status of an individual. The method comprises the following steps: taking a volume of a whole blood sample from the individual; stimulating the whole blood sample by incubating the latter with a quantity of phytohemagglutinin (PHA) at a temperature between 35°C and 39°C for a minimum of 3 to 3.5 hours; evaluating the level of interferon-gamma production induced by this incubation/stimulation, the evaluated level subsequently providing an indication of the individual's immune status.
The present invention relates to antibodies or antigen binding fragments thereof that binds to human “TIMP2. Further provided are methods for treating subjects, including human subjects, in need of treatment with the isolated TIMP2 antibodies or antigen-binding fragments thereof disclosed herein. Further provided are pharmaceutical or sterile compositions of anti-TIMP2 antibodies and antigen-binding fragments of the invention, the antibody or antigen-binding fragment thereof is admixed with a pharmaceutically acceptable carrier or excipient. Further provided are kits comprising one or more components that include an anti-TIMP2 antibody or antigen-binding fragment thereof of the invention or a pharmaceutical composition thereof.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
67.
METHOD FOR MANUFACTURING A BIOLOGICAL ANALYSIS CARD INVOLVING A HEATING BLOCK
The invention relates to a method for manufacturing a biological analysis card (1) comprising: - a step a) of providing a base (2) formed of: - at least two films (3) placed one on top of the other; - a receiving space (4) formed between the two films (3); - ducts (5) leading to the receiving space (4); - a step b) of placing a plate (9) in the receiving space (4), the plate (9) comprising: - a first face (10a) and a second face connected by an edge (11) having a profile; - a plurality of wells (12) opening onto at least the first face (10a) or the second face; - a plurality of channels (13) fluidly connecting the wells (12); - a welding step c) for welding the two films (3) in the receiving space (4) to the plate (9) and a film (3) to segments of the edge (11) of the plate (9) by applying a heating block to the film (3) against the edge (11) on the side of the first face (10a).
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Chemicals used in industry, Chemical preparations for research; Chemical diagnostic reagents, Biological diagnostic preparations, not for medical purposes; Chemical preparations for scientific purposes; Reagents and Environments, For the following purposes: Checking, detecting, diagnosing, and Analysis, Relating to contaminants in industrial, agri-food, cosmetic, pharmaceutical and environmental products. Reagents and media for medical, pharmaceutical and veterinary diagnosis; Laboratory reagents for immunological analysis for use by clinical or medical laboratories; Biological preparations for medical or veterinary purposes.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Chemical preparations for industry and research; chemical reagents and biological preparations for diagnosis, other than for medical use; chemical preparations for scientific use; reagents and culture media for controlling, detecting, diagnosing and analyzing contaminating substances in industrial, agri-food, cosmetic, pharmaceutical and environmental products Reagents and culture media for medical, pharmaceutical and veterinary diagnosis; laboratory reagents for clinical or medical laboratories; biological preparations for medical or veterinary use
70.
DIGITAL HOLOGRAPHIC IMAGING TECHNIQUE WITH TWIN IMAGE ELIMINATION
A digital holographic imaging technique, includes iterative steps of: a) through back-propagation to the object coordinate of a hologram field comprising a spatial distribution of amplitude corresponding to the spatial distribution of intensity of the hologram and a spatial distribution of phase, determining an object field involving a spatial distribution of absorption and of phase shift of the imaged object, b) thresholding the values of the spatial distribution of absorption and of phase shift by decreasing the values to below a respective threshold, the thresholds decreasing in each iteration, c) through repropagation of the object field to the hologram coordinate, determining a modified hologram field comprising a modified spatial distribution of amplitude and a modified spatial distribution of phase, d) replacing the spatial distribution of phase of the hologram field with the modified spatial distribution of phase, the spatial distribution of phase shift and of absorption of the imaged object being those of the object field of the last iteration.
A method for classifying at least one input image containing a target particle in a sample, involves implementing, via data-processing of a client, steps of: (b) extracting a vector of characteristics of the target particle, the characteristics being numerical coefficients each associated with one elementary image of a set of elementary images each representing a reference particle, such that a linear combination of the elementary images weighted by the coefficients approximates the representation of the target particle in the input image; (c) classifying the input image depending on the extracted vector of characteristics.
A method for classifying at least one input image representing a target particle in a sample involves implementing, by data processing a client, steps of: (B) extracting a characteristic map of the target particle from the input image; (c) reducing the number of variables in the extracted characteristic map, using the t-SNE algorithm; (d) classifying, unsupervised, the input image based on the characteristic map having a reduced number of variables.
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
A method for classifying a sequence of input images representing a target particle in a sample over time, includes the following steps performed by the data processing of a client, namely: (b) concatenation of the input images in the sequence as a three-dimensional stack; (c) direct classification of the three-dimensional stack using a convolutional neural network, CNN
G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
G06V 10/77 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using data integration or data reduction, e.g. principal component analysis [PCA] or independent component analysis [ICA] or self-organising maps [SOM]; Blind source separation
74.
REACTION MEDIUM AND ASSOCIATED METHOD FOR DETECTION OF A TARGET MICROORGANISM
The invention relates to a gelled reaction medium for the detection, identification, enumeration and/or isolation of at least one target microorganism in a sample that may contain same, comprising at least one binding partner specific to a component of a target microorganism or of a component derived from said microorganism, coupled to at least one nanoparticle to form at least one binding conjugate.
C12Q 1/04 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
The present invention is directed to sample test cards having an increased sample well capacity for analyzing biological or other test samples. In one embodiment, the sample test cards of the present invention comprise one or more fluid over-flow reservoirs, wherein the over-flow reservoirs are operatively connected to a distribution channel by a fluid over-flow channel. In another embodiment, the sample test cards may comprise a plurality of flow reservoirs operable to trap air thereby reducing and/or preventing well-to-well contamination. The test card of this invention may comprise from 80 to 140 individual sample wells, for example, in a test card sample test cards of the present invention have a generally rectangular shape sample test card having dimensions of from about 90 to about 95 mm in width, from about 55 to about 60 mm in height and from about 4 to about 5 mm in thickness.
Systems and methods for determining a topology for a multi-path connection based on one or more application-level wherein, a method performed by a master topology function includes receiving a request for a topology for a multi-path connection that satisfies an application-level requirement(s) of a particular application and determining a topology for the multi-path connection based on the application-level requirement(s). The topology includes two or more links from a source wireless node to a target wireless communication device and at least one of the two or more links is a multi-hop link from the source wireless node to the target wireless communication device via one or more additional wireless communication devices that operate as relays. The method further includes configuring the source wireless node, the target wireless communication device, and the one or more additional wireless communication devices in accordance with the determined topology.
in vitro in vitro method for determining whether a newborn patient has late-onset neonatal sepsis, which comprises determining the PTX-3 protein concentration in a biological sample previously obtained from said patient.
The present invention concerns reagents for the reversible protection of biological molecules. It relates in particular to compounds derived from azaisatoic anhydride and their uses for the protection of biological molecules, particularly enzymes, in order to block their activity. The invention also relates to the biological molecules protected in this manner and to the methods for making use of these reagents.
Devices, containers, and methods are provided for performing biological analysis in a closed environment. Illustrative biological analyses include nucleic acid amplification and detection and immuno-PCR.
A method for detecting target genomic sequences at predetermined positions in a sequenced genome of a microbial organism in the form of reads. The method comprises computing a local sequencing depth of the genome in a neighborhood of the position of a target genomic sequence, said computing comprising the steps of a) detecting in the reads a set of digital genomic sequences from at least one reference genome of the microbial organism, b) generating of third set of digital genomic sequences comprising reads and digital genomic sequences of the second set belonging to the neighborhood c) counting the number of copies of each digital genomic sequences of the third set of digital genomic sequences, and d) computing the local sequencing depth as being equal to the maximum of the counted numbers of copies.
An in vitro or ex vivo method for determining the risk of complication in a patient, including a step of measuring the expression of C3AR1 in a biological sample from the patient.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Chemical preparations for industry and research; chemical
reagents and biological preparations for diagnosis, other
than for medical use; chemical preparations for scientific
use; reagents and culture media for controlling, detecting,
diagnosing and analyzing contaminating substances in
industrial, agri-food, cosmetic, pharmaceutical and
environmental products. Reagents and cell culture media for medical, pharmaceutical
and veterinary diagnosis; diagnostic reagents for
immunological analysis for use in clinical or medical
laboratories; biological preparations for medical or
veterinary use.
83.
METHOD FOR ANALYSING A BIOLOGICAL SAMPLE WITH ARTEFACT MASKING
A method for analysing a biological sample by means of an analysis instrument, the sample including biological agents and being arranged in an analysis receptacle in view of a holographic imaging system, the method including: acquiring a holographic image of the sample, the holographic image associating an intensity value with each pixel, determining, from the image acquired, an image mask which associates an active or inactive state with each pixel in accordance with the intensity values so that an inactive state is associated with pixels which correspond to artefacts caused by elements present in the field of view other than biological agents, determining a value of at least one biomass parameter which represents the quantitative spatial distribution of biological agents in the field of view, using only the pixels of the holographic image having an active state, and supplying the value of the biomass parameter from the analysis results.
The invention relates to an in vitro or ex vivo method for determining the risk of incidence of a care-related infection in a patient, including a step of measuring the expression of CIITA in a biological sample from said patient.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
85.
METHODS AND COMPOSITIONS FOR ASSESSING AND TREATING PERSISTENT ACUTE KIDNEY INJURY BASED ON C-C MOTIF CHEMOKINE LIGAND 14 MEASUREMENT
The present invention relates to methods and compositions for assessing a risk for developing persistent acute kidney injury and methods of treating a subject based on the assessment. In particular, disclosed herein are methods and compositions for detecting C-C motif chemokine ligand 14 (CCL14) for predicting the risk of persistent acute kidney injury based on changes in the level of CCL14 in two or more measurements of CCL14 in a subject and/or based on two cutoff levels of CCL14.
in vitro in vitroin vitro methods and kit for predicting the risk of developing Post-Chikungunya Chronic Inflammatory Joint Disease (pCHIKV-CIJD) in a subject. The method comprises a step of evaluating the expression of one or more biomarkers in a biological sample obtained from said subject, for example a blood sample, wherein said one or more biomarkers are selected among specific long non-coding RNAs, and wherein a higher expression than control expression value indicates a risk of developing pCHIKV-CIJD.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
87.
METHOD FOR DETERMINING THE RISK OF INCIDENCE OF A CARE-RELATED INFECTION IN A PATIENT
An in vitro or ex vivo method for determining the risk of incidence of a care-related infection includes a step of measuring the expression of CD177 in a biological sample from said patient.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
88.
Focus Adjustment Method For Holographic Imaging System
Centre National de la Recherche Scientifique (CNRS) (France)
Inventor
Faure, Nicolas
Pinston, Frédéric
Fournier, Corinne
Denis, Loïc
Olivier, Thomas
Abstract
A focus adjustment method for acquiring an image of a surface of interest of a sample by a holographic imager includes the steps of:
placing the sample including at least one reference object having a known shape and described by characterising parameters having at least position parameters
acquiring an image and determining the position of the reference object with respect to the acquisition plane, by applying a light diffraction model involving the spatial parameters of the reference object estimated by approximating the appearance of the reference object in the holographic image acquired, and
determining the position of the surface of interest with respect to the acquisition plane from a position of the reference object and focus adjustment of the image acquisition.
The invention relates to a system for extracting components from a biological sample, the system comprising at least one extraction platform (101), a magnetic extraction module (1) comprising a magnetic portion (2) and a securing portion (S) for securing the module (1) to the extraction platform (101), the magnetic portion (2) comprising at least one magnet (4) that is fixedly mounted relative to the securing portion (S), the extraction platform (101) comprising a pipetting support (103) that is configured to co-operate with a pipetting device, characterised in that the magnetic portion of the magnetic extraction module has at least one position of use in which the magnetic portion is fixed at least relative to the pipetting support (103).
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Chemical products for use in research and industry, namely, reagents for non-medical purposes used in microbiological analyses, culture media for research, monitoring, detection and diagnosis of pathogens and contaminants
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Chemicals used in industry, Chemical preparations for research; Chemical diagnostic reagents, Biological diagnostic preparations, not for medical purposes; Chemical preparations for scientific purposes; Reagents and Environments, For the following purposes: Checking, detecting, diagnosing, and Analysis, Relating to contaminants in industrial, agri-food, cosmetic, pharmaceutical and environmental products. Reagents and media for medical, pharmaceutical and veterinary diagnosis; Laboratory reagents for immunological analysis for use by clinical or medical laboratories; Biological preparations for medical or veterinary purposes.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Chemical preparations for industry and research; chemical reagents and biological preparations for diagnosis, other than for medical use; chemical preparations for scientific use; reagents and culture media for controlling, detecting, diagnosing and analyzing contaminating substances in industrial, agri-food, cosmetic, pharmaceutical and environmental products Reagents and cell culture media for medical, pharmaceutical and veterinary diagnosis; diagnostic reagents for immunological analysis for use in clinical or medical [ laboratory use ] * laboratories * ; biological preparations for medical or veterinary use
94.
METHOD FOR DETERMINING THE RISK OF INCIDENCE OF A CARE-RELATED INFECTION IN A PATIENT
An in vitro or ex vivo method for determining the risk of incidence of a healthcare-associated infection includes a step of measuring the expression of TAP2 in a biological sample from said patient.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
The present invention is directed to a system and method for load balancing specimen containers between a plurality of automated detection apparatuses. The method may include receiving a specimen container at a container pick-up station in a first automated detection apparatus; determining loading ability, transfer status, and cell availability of the first automated detection apparatus and one or more downstream automated detection apparatuses; and transferring the specimen container from the first automated detection apparatus to a downstream automated detection apparatus when a first ratio of effective available cell count to effective capacity in the first automated detection apparatus is less than a second ratio of total effective available cell count to total effective capacity of a sum of the first automated detection apparatus and the one or more downstream automated detection apparatuses.
G05B 19/418 - Total factory control, i.e. centrally controlling a plurality of machines, e.g. direct or distributed numerical control (DNC), flexible manufacturing systems (FMS), integrated manufacturing systems (IMS), computer integrated manufacturing (CIM)
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
96.
TOOL FOR SEIZING AND EJECTING CLOSURE PLUGS FOR TUBES RECEIVING SAMPLES TO BE ANALYSED, AND USE OF SUCH A TOOL
The subject of the invention relates to a tool for manipulating a plurality of plugs, taking the form of a comb (1) comprising:
a body (7) provided with a row of teeth (4) having pointed distal portions (4p) spaced apart in a linear direction in order to engage with the cavities of the plugs;
a system for separating the plugs from the teeth (4) that comprises a slide returned elastically and guided to slide with respect to the body (7) in a direction parallel to the direction of extension of the teeth, the slide being provided with the fingers of the comb, which are movable by sliding between the teeth (4), and a control (11a) accessible from a first portion (1a) of the comb and which, when pressed to move translationally, causes the fingers of the comb to slide in the direction of the pointed distal portions (4p) in order to eject the plugs from the teeth (4).
B67B 7/10 - Hand- or power-operated devices for opening closed containers for removing stoppers with means for retrieving stoppers from the interior of the container
97.
DEVICE FOR HOLDING TUBES USED FOR ANALYSING SAMPLES BY MEANS OF NUCLEIC ACID AMPLIFICATION TECHNIQUES AND METHOD FOR USING SUCH A DEVICE
The invention relates to a device comprising:
a support tray (7) for tubes receiving samples to be analyzed, this tray (7) having holes (8) adapted to each receive a tube bearing on the upper surface and with its bottom protruding from the tray;
a lid (10) provided with chimneys (11) arranged according to a distribution similar to the distribution of the holes of the tray, this lid (10) being designed to occupy at least one position of superposition above the tray (7), so that the lid can be removably assembled to the tray to form a unitary assembly for holding the tubes and to position the chimneys (11) above the tubes in order to guide the pipette tips penetrating inside the tubes.
The invention relates to an analysis card (1) for analysing a biological sample by means of an in-vitro diagnostic instrument, the analysis card (1) comprising a plurality of wells (2) formed in a board (3), each well (2) containing at least one reagent (4) the analysis card (1) comprising a channel (5) for conveying a liquid sample to the wells (2), characterised in that each well (2) forms, in the board (3), an internal space defined by a lateral surface, the lateral surface comprising at least one wall, and in that each well (2) has the at least one reagent (4) deposited only on its lateral surface.
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Coagulation factor VII, CA 19-9, Insulin-like growth factor-binding protein 7, C—X—C motif chemokine 6, and C—C motif chemokine 13 as diagnostic and prognostic biomarkers in renal injuries.
The invention relates to a metagenomic analysis of a sample for the purpose of detecting the presence of a species of interest in the sample. The analysis is carried out iteratively. During each iteration, sequences corresponding to each species of interest are identified and counted. The iterations stop when the presence of a species of interest is confirmed or when a maximum number of iterations have been carried out. The detection of a species of interest can be followed by a more precise characterisation of the genome of said species of interest. The characterisation implements supplementary iterations.
